Yes, HIV patients do have an increased risk of colon cancer, though the magnitude of this risk is modest and appears to be declining over time.
People living with HIV (PLWH) should follow standard colorectal cancer screening guidelines, as their overall risk profile is similar to the general population, particularly in the modern antiretroviral therapy (ART) era.
Understanding the Risk Profile
According to the 2018 NCCN Guidelines, colorectal cancer accounts for approximately 5% of all cancers diagnosed in PLWH 1. The guidelines emphasize that PLWH experience an approximately 50% increase in overall cancer incidence compared to the general population, driven by underlying immune deficiency, viral coinfections, and higher prevalence of traditional risk factors like smoking and heavy alcohol consumption 1.
However, the most recent and comprehensive data from 2025 provides important context: the standardized incidence ratio (SIR) for colon cancer in HIV patients was NOT significantly elevated in recent years 2. A 2017 meta-analysis of 27 studies involving over 1.6 million person-years confirmed this finding, showing no increased summary risk of colorectal malignancy among those with HIV (SIR 1.00; 95% CI 0.82-1.22) 3.
Key Clinical Considerations
Age at Diagnosis
One critical caveat: HIV-positive patients develop colon cancer approximately 10 years younger than HIV-negative patients (mean age 51.3 vs 61.6 years, p<0.001) 4. This earlier onset appears related to higher rates of smoking, alcohol use, and lower BMI in the HIV population 4.
Screening Findings
The evidence on screening colonoscopy yields is mixed:
Older data (2006) showed HIV patients had significantly higher rates of neoplastic lesions on screening sigmoidoscopy (25.5% vs 13.1%, p<0.001) and more advanced neoplasia (7.3% vs 3.8%, p=0.03) 5
More recent studies (2020,2025) found no difference in prevalence of colorectal neoplasia between HIV and non-HIV patients undergoing screening colonoscopy 6, 7. The 2020 study showed a standardized prevalence ratio of 0.99 (95% CI 0.81-1.19) 6
This divergence likely reflects improvements in HIV care with modern ART, reducing chronic inflammation and immune dysfunction.
Practical Screening Recommendations
Follow standard average-risk colorectal cancer screening guidelines for PLWH 6, 7. This means:
- Begin screening at age 45-50 (per general population guidelines)
- Consider screening at the younger end of this range given the 10-year earlier onset observed in some cohorts 4
- Use standard screening modalities (colonoscopy, FIT testing, etc.)
- Apply standard screening intervals based on findings
Important Caveats
Do NOT reduce screening intensity based solely on HIV status - the evidence does not support this 6, 7. However, be aware that:
- Screening rates are actually lower in HIV populations, particularly in Medicaid cohorts (adjusted OR 0.80,95% CI 0.77-0.83) 8
- Mortality from colorectal cancer may be higher in PLWH (SMR 2.09, though not statistically significant) 3, emphasizing the importance of not missing screening opportunities
- Traditional risk factors (smoking, alcohol) are more prevalent in HIV populations and should be addressed 1, 4
Treatment Considerations
If colon cancer is diagnosed in a PLWH:
- Continue ART during cancer treatment - do not interrupt HIV therapy 1
- Co-manage with both oncology and HIV specialists 1
- INSTI-based regimens (dolutegravir, bictegravir) are safe and effective during chemotherapy with minimal drug-drug interactions 9
- Treat the cancer per standard guidelines without modifications based solely on HIV status 1
The bottom line: Modern HIV care has largely normalized colorectal cancer risk, but vigilance is needed given earlier age at diagnosis and historically lower screening rates in this population.